• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

0.7999 -0.0151 (-1.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 118,995
Open 0.8068
Bid (Size) 0.7680 (2,500)
Ask (Size) 0.7900 (200)
Prev. Close 0.8150
Today's Range 0.7540 - 0.8149
52wk Range 0.5480 - 2.910
Shares Outstanding 5,979,292
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗
February 18, 2026
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level. 
Via Stocktwits
The market is filled with gapping stocks in Wednesday's session. ↗
February 18, 2026
Via Chartmill

Performance

YTD
-6.2%
-6.2%
1 Month
-2.5%
-2.5%
3 Month
-33.9%
-33.9%
6 Month
-49.4%
-49.4%
1 Year
-68.6%
-68.6%

More News

Read More
News headline image
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
February 18, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
February 12, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
February 04, 2026
From Aprea Therapeutics
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
January 30, 2026
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
January 30, 2026
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
January 30, 2026
Via Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗
January 30, 2026
Via Chartmill
What's going on in today's after hours session ↗
January 29, 2026
Via Chartmill
News headline image
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
January 29, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 29, 2026
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
December 18, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now
December 10, 2025
Via AB Newswire
News headline image
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 09, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.
November 20, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target
November 18, 2025
Via AB Newswire
News headline image
Signal Advance (OTC: SIGL) CEO on The Street Podcast – Unveiling Physics-Based Encryption Built for the AI and Quantum Computing Era
November 12, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
November 12, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
November 03, 2025
Via AB Newswire
Topics Artificial Intelligence
News headline image
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
October 24, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
October 17, 2025
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
October 15, 2025
From Aprea Therapeutics
Via GlobeNewswire
News headline image
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From Aprea Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?
Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?
The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market
What is the current price of Aprea Therapeutics, Inc. - Common Stock?
The current price of Aprea Therapeutics, Inc. - Common Stock is 0.7999
When was Aprea Therapeutics, Inc. - Common Stock last traded?
The last trade of Aprea Therapeutics, Inc. - Common Stock was at 02/24/26 04:00 PM ET
What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?
The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 4.78M
How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?
Aprea Therapeutics, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap